Shaun Chuah

Publications

Published as Cher Shiong (Shaun) Chuah, cited as Chuah CS.

2026
ChatIBD: design, safeguards, and early international use of a guideline-grounded generative AI tool for inflammatory bowel disease (IBD) professionalsChuah CS, Gros B, Plevris N · medRxivMachine-learning approach to dissect the clinical heterogeneity of IBD-associated fatigueChuah CS, Hall R, Whelan RJ, Cartlidge PD, Gros B, Iglesias-Flores E, Parkash N, Boyapati RK, Ramos-Belinchon C, Ong S, Brownson EF, Campbell IAM, Mowat C, Seenan JP, MacDonald JC, MUSIC Patient-Public Involvement Group, Ho GT · BMJ Digital Health & AIPatient-led thematic analysis on the impact of living with inflammatory bowel disease: a contemporary appraisal of 415 patient-reported outcomes to improve care and researchHalligan MJ, Thompson AE, Docherty D, Kelly P, Pryde E, Chuah CS, Hall R, Ho GT · Crohn's & Colitis 360A chemiluminescence assay targeting granzyme A activity for monitoring inflammatory bowel diseaseScott JI, Cheng Z, Thompson EJ, Karmakar U, Cowell V, David M, Gordon D, Mendive-Tapia L, Le Saint-Grant A, Volkmer P, Chuah CS, et al. · Nature Biomedical Engineering
2025
A real-world retrospective cohort study of inflammatory bowel disease colorectal cancer surveillancePorter RJ, Song M, Gillespie S-L, Ball G, Plevris N, Blackwell J, Watson EF, Churchhouse AMD, Gardner M, Crawford A, Chuah CS, et al. · Frontline Gastroenterology
2024
Formylated Peptide Receptor-1 (FPR1) mediated gut inflammation as a therapeutic target in Inflammatory Bowel DiseaseMcAllister MJ, Hall R, Whelan RJ, Fischer LJ, Chuah CS, Cartlidge PD, Drury B, Rutherford DG, Duffin RM, Cartwright JA, Dorward DA, Rossi AG, Ho GT · Crohn's & Colitis 360
2023
Investigating the role of circulating cell-free DNA as a mechanistic biomarker in inflammatory bowel disease: development of an integrated precision-medicine enabled platform in ScotlandChuah CS · MD thesis, University of EdinburghCirculating Cell-Free DNA in Inflammatory Bowel Disease: Liquid Biopsies with Mechanistic and Translational ImplicationsChuah CS, Fischer L, Ho GT · Faculty ReviewsNeutrophil-dependent Mitochondrial DNA Release Associated With Extracellular Trap Formation in Inflammatory Bowel DiseaseDrury B, Chuah CS, Hall R, Hardisty GR, Rossi AG, Ho GT · Gastro Hep Advances
2022
Letter: non-selective beta-blockers in cirrhosis—effect beyond portal hypertension. Authors' replyDunne P, Young D, Chuah CS, Hayes PC, Tripathi D, Leithead JA, Smith LA, Gaya DR, Forrest EH, Stanley AJ · Alimentary Pharmacology & TherapeuticsCarvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trialDunne P, Young D, Chuah CS, Hayes PC, Tripathi D, Leithead JA, Smith LA, Gaya DR, Forrest EH, Stanley AJ · Alimentary Pharmacology & Therapeutics
2021
Intestinal protein characterisation of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in inflammatory bowel disease and fatal COVID-19 infectionMcAllister MJ, Kirkwood K, Chuah CS, Thompson EJ, Cartwright JA, Russell CD, Dorward DA, Lucas CD, Ho GT · InflammationCarvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up studyMcDowell H, Chuah CS, Tripathi D, Stanley AJ, Forrest EH, Hayes PC · Alimentary Pharmacology & Therapeutics
2020
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohortPlevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Lam WL, Saunders J, Kelly C, Gaya D, Jafferbhoy H, MacDonald JC, Seenan JP, Mowat C, Naismith G, Potts LF, Sutherland DI, Watts D, Arnott I, Bain G, Jones G, Lees CW · Journal of Gastroenterology and HepatologyNormalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s DiseasePlevris N, Fulforth J, Lyons M, Siakavellas S, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones GR, Lees CW · Clinical Gastroenterology and Hepatology
2019
Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab CohortPlevris N, Chuah CS, Allen RM, Lees CW, et al. · Journal of Crohn's and ColitisAssociation of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel diseasePlevris N, Jenkinson PW, Chuah CS, Lyons M, Merchant LM, Pattenden R, Arnott ID, Jones GR, Lees CW · Frontline GastroenterologyHigher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic RemissionPlevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW · Inflammatory Bowel DiseasesImplementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World OutcomesPlevris N, Jones GR, Jenkinson PW, Lyons M, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Din S, Shand AG, Arnott ID, Lees CW · Digestive Disease and Sciences
2018
Case of steroid-resistant Crohn's-associated bronchiolitis in the setting of quiescent gastrointestinal disease treated with infliximabChuah CS, Noble C, Leitch A · BMJ Case Reports
2013
Hydrogen ion concentration and coronary artery bypass graft surgery with and without cardiopulmonary bypassCS Chuah, R Kirkbride, P Alston, J Irons · Journal of Cardiothoracic Surgery
Full record on ORCID →